CoChat

Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes

Open access
Akturk, Halis K., Taylor, Daniel D., Camsari, Ulas M., Rewers, Amanda, Kinney, Gregory L., Shah, Viral N. · 2019 · JAMA Internal Medicine
Cited by 49

The DOI matches its Crossref record.

Abstract

ket.A biosimilar of Sanofi's popular insulin Lantus was approved for use in the European Union in 2014 but was initially delayed for 2 more years by a lawsuit in the United States.6 Now that the biosimilar product, Basaglar, has finally hit the market, its price is only minimally lower than the original brand.7 The same insulin pen that retails for $140 in the United States costs less than $15 in Germany and Canada.8 The US insurance system-private and public-does not cut people with chronic disease a break but instead tends to penalize them.People with type 1 diabetes are people who drew a short straw in the disease lottery.Most other developed countries have concluded that their citizens should therefore not be subject to copays or high deductibles."If you have a chronic disease, you shouldn't be burdened by the cost," York F. Zöllner, a professor of health economics at Hamburg University of Applied Sciences, told me in an interview for the New York Times before explaining the German approach, in which out-of-pocket contributions for insulin are less than $100 per year.9 Until very recently, the disease foundations (JDRF and the American Diabetes Association among them), as well as many diabetes patient groups, did not protest much as the prices rose, in part likely because so many receive funding from pharmaceutical companies.Extreme prices can lead to extreme solutions.A 29-year-old student in Missouri with diabetes whom I interviewed for my book 10 told me that she would only consider doctoral programs outside of the United States."My one goal in life has been to move to Europe so I don't have to pay these staggering prices just to survive," she said.But others-that 25%-will quietly skimp on their insulin, taking less than they need but more, perhaps, than they can really afford.Some of them will die.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2018.5142

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 49

Metadata

Authors
Akturk, H. K., Taylor, D. D., Camsari, U. M., Rewers, A., Kinney, G. L., & Shah, V. N.
Venue
JAMA Internal Medicine
Published
2019-01-01
Volume
179
Issue
1
Pages
115
ISSN
2168-6106 (ISSN-L)
OpenAlex
W2899972966
Cited by
49
References
0
FWCI
4.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes. https://app.cochat.ai/papers/10.1001/jamainternmed.2018.5142
The paper
Akturk, H. K., Taylor, D. D., Camsari, U. M., Rewers, A., Kinney, G. L., & Shah, V. N. (2019). Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2018.5142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.